Fixed-dose combination (antiretroviral)

Fixed-dose combinations of antiretrovirals are multiple antiretroviral drugs combined into a single pill, which helps reduce pill burden. They may combine different classes of antiretrovirals or contain only a single class. Licensed fixed-dose combinations are shown in the table below. Six are complete single-tablet regimens for the treatment of HIV (Atripla, Complera/Eviplera, Stribild, Triumeq, Genvoya, Odefsey); the others must be combined with one or more additional pills to complete a regimen.

Brand Name	Drug Names (INN)	Date of FDA Approval	Company
Combivir	lamivudine + zidovudine	September 26, 1997	GlaxoSmithKline
Kaletra	lopinavir + ritonavir	September 15, 2000	Abbott Laboratories
Trizivir	abacavir + lamivudine + zidovudine	November 15, 2000	GlaxoSmithKline
Epzicom (U.S.) Kivexa (EU, RU)	abacavir + lamivudine	August 2, 2004	GlaxoSmithKline
Truvada	tenofovir disoproxil + emtricitabine	August 2, 2004	Gilead Sciences
Atripla	emtricitabine + tenofovir disoproxil + efavirenz	July 12, 2006	Gilead Sciences and Bristol-Myers Squibb
Complera (U.S.) Eviplera (EU, RU)	emtricitabine + rilpivirine + tenofovir disoproxil	August 10, 2011	Gilead Sciences and Janssen Therapeutics (formerly Tibotec)
Stribild	elvitegravir + cobicistat + emtricitabine + tenofovir disoproxil	August 27, 2012	Gilead Sciences
Triumeq	abacavir + dolutegravir + lamivudine	August 22, 2014	ViiV Healthcare
Evotaz	atazanavir + cobicistat	January 29, 2015	Bristol-Myers Squibb
Prezcobix	darunavir + cobicistat	January 29, 2015	Janssen Therapeutics
Dutrebis	lamivudine + raltegravir	February 6, 2015	Merck & Co.
Genvoya	elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide	November 5, 2015	Gilead Sciences
Odefsey	emtricitabine + rilpivirine + tenofovir alafenamide	March 1, 2016	Gilead Sciences
Descovy	emtricitabine + tenofovir alafenamide	April 4, 2016	Gilead Sciences

References

Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)

Entry/fusion inhibitors
(Discovery and development)

gp41 (Enfuvirtide (ENF, T-20))
CCR5 (Maraviroc (MVC)
Vicriviroc^†, Cenicriviroc^†, PRO 140^†)
CD4 (Ibalizumab^†)
gp120 (Fostemsavir^†)

Reverse-transcriptase
inhibitors (RTIs)

Nucleoside and nucleotide (NRTI)	Nucleoside analogues/NRTIs: Abacavir (ABC)°^# Didanosine (ddI) Emtricitabine (FTC)° Lamivudine (3TC)°^# Stavudine (d4T)^# Zidovudine (AZT, ZDV)^# Amdoxovir^† Apricitabine^† Censavudine^† Elvucitabine^† Racivir^† Stampidine^† Zalcitabine (ddC)^◊ Nucleotide analogues/NtRTIs: Tenofovir disoproxil (TDF)°^# Tenofovir alafenamide (TAF)

Non-nucleoside (NNRTI) (Discovery and development)	(1st generation) Efavirenz (EFV)°^# Nevirapine (NVP)^# Delavirdine (DLV)^◊ (2nd generation) diarylpyrimidines (Etravirine (ETR) Rilpivirine (RPV)°) Doravirine

Integrase inhibitors
(Integrase strand transfer inhibitors (INSTI))

Dolutegravir (DTG)°
Elvitegravir (EVG)°
Raltegravir (RAL)°
BI 224436^†
Globoidnan A (experimental)
Cabotegravir^†
Bictegravir^†
MK-2048^†

Maturation inhibitors

Bevirimat^†
BMS-955176^§

Protease Inhibitors (PI)
(Discovery and development)

1st generation	Amprenavir (APV)^◊ Fosamprenavir (FPV) Indinavir (IDV)^◊ Lopinavir (LPV) Nelfinavir (NFV) Ritonavir (RTV)^# Saquinavir (SQV)^#

2nd generation	Atazanavir (ATV)°^# Darunavir (DRV)°^# Tipranavir (TPV)

Combined formulations

Abacavir/lamivudine°^#
Abacavir/dolutegravir/lamivudine°
Abacavir/lamivudine/zidovudine
Atazanavir/cobicistat
Darunavir/cobicistat
Efavirenz/emtricitabine/tenofovir°^#
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
Elvitegravir/cobicistat/emtricitabine/tenofovir°
Emtricitabine/tenofovir alafenamide
Emtricitabine/rilpivirine/tenofovir alafenamide
Emtricitabine/rilpivirine/tenofovir°
Lamivudine/raltegravir
Lamivudine/zidovudine^#
Lopinavir/ritonavir°^#
Tenofovir/emtricitabine°^#

Pharmacokinetic boosters

Experimental agents

Uncoating inhibitors	TRIM5alpha (gene)

Transcription inhibitors	Tat antagonists

Translation inhibitors	Trichosanthin

Other	Abzyme BIT225^† Calanolide A Ceragenin Cyanovirin-N Diarylpyrimidines Epigallocatechin gallate (EGCG) KP-1461^† Foscarnet Fosdevirine^† Griffithsin Hydroxycarbamide Miltefosine Portmanteau inhibitors Scytovirin Seliciclib^† Synergistic enhancers Tre recombinase Zinc finger protein transcription factor

Failed agents	Aplaviroc Atevirdine Brecanavir Capravirine Dexelvucitabine Droxinavir Lasinavir Emivirine Lersivirine Lodenosine Loviride Mozenavir Palinavir Telinavir

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

°DHHS recommended initial regimen options. ^◊Formerly or rarely used agent.

This article is issued from Wikipedia - version of the 8/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.

Fixed-dose combination (antiretroviral)

See also

References